The University Council of the University of Basel has approved the appointment of Prof. Dr. Lars G. Hemkens to a titular professorship at the Faculty of Medicine for Clinical Epidemiology.
Lars G. Hemkens, MD, MPH, is a Senior Scientist at the Department of Clinical Research, University of Basel, and leads Pragmatic Trials and Real World Evidence at the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB). Additionally, Dr. Hemkens is affiliated with the Meta-Research Innovation Center at Stanford (METRICS; Stanford University, USA).(https://lnkd.in/ecgsCUT7)
Previously, Dr. Hemkens served as the Deputy Director of the Basel Institute for Clinical Epidemiology and Biostatistics (ceb) until its closure. He has also worked at the Stanford Prevention Research Center (Stanford University) and the Institute for Quality and Efficiency in Health Care (IQWiG, Cologne, Germany; Department of the Director). At RC2NB, he leads the workstream Pragmatic Trials and Real World Evidence and the Pragmatic Evidence Lab. (www.pragmatic-evidence.org) His research includes developing and investigating digital biomarkers and digital health applications in multiple sclerosis. Dr. Hemkens is also the Co-PI of MultiSCRIPT, a nationwide pragmatic platform trial fully embedded in the Swiss MS cohort, aimed at continuously improving care for persons with multiple sclerosis.
In his role at the Department of Clinical Research, Dr. Hemkens co-designs various clinical studies across a wide range of medical fields and closely supervises the design of nationwide investigator-initiated clinical trials. He is an associate editor and thematic series editor of “Big data for randomized trials” at the journal Trials, and serves on the editorial board of BMJ Evidence-Based Medicine and the working committee of the RECORD reporting guideline group. Dr. Hemkens also teaches comparative effectiveness research and pragmatic trial design at the University of Basel and Sorbonne Paris Cité, France.
RC2NB is honored to have Dr. Hemkens as a valued member of our team. We support his substantial contributions and eagerly anticipate his ongoing influence in the field of clinical research, neuroscience and digital health.
Link to the University of Basel announcement: here
